Recent Advances in the Management of Hormone-Sensitive Oligometastatic Prostate Cancer

References

• Tosoian JJ, Gorin MA, Ross AE, et al. Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nat Rev Urol. 2017;14:15–25. doi:10.1038/nrurol.2016.175
   PubMed Web of Science ®Google Scholar
• Foster CC, Weichselbaum RR, Pitroda SP. Oligometastatic prostate cancer: reality or figment of imagination? Cancer. 2019;125:340–352. doi:10.1002/cncr.31860
   PubMed Web of Science ®Google Scholar
• Fraser M, Koontz B, Emmenegger U, et al. What Is Oligometastatic Prostate Cancer? Eur Urol Focus. 2019;5:159–161. doi:10.1016/j.euf.2018.12.009
   PubMedGoogle Scholar
• Sumiyoshi T, Chi KN, Wyatt AW. Clinical implications of genomic alterations in metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2021;24:310–322. doi:10.1038/s41391-020-00308-x
   PubMed Web of Science ®Google Scholar
• Kothari G, Ost P, Cheung P, et al. Trends in management of oligometastatic hormone-sensitive prostate cancer. Curr Oncol Rep. 2019;21(43). doi:10.1007/s11912-019-0791-5
   PubMed Web of Science ®Google Scholar
• Lievens Y, Guckenberger M, Gomez D, et al. Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2020;148:157–166. doi:10.1016/j.radonc.2020.04.003
   PubMed Web of Science ®Google Scholar
• APCCC 2019: oligometastatic Prostate Cancer – definitions and Concepts. Available from: https://www.urotoday.com/conference-highlights/apccc-2019/114616-apccc-2019-oligometastatic-prostate-cancer-definitions-and-concepts.html. Accessed December 10, 2021.
   Google Scholar
• Rogowski P, Roach M, Schmidt-Hegemann NS, et al. Radiotherapy of oligometastatic prostate cancer: a systematic review. Radiat Oncol. 2021;16(50):1–6. doi:10.1186/s13014-021-01776-8
   PubMed Web of Science ®Google Scholar
• Marvaso G, Volpe S, Pepa M, et al. Oligorecurrent prostate cancer and stereotactic body radiotherapy: where are we now? A systematic review and meta-analysis of prospective studies. Eur Urol Open Sci. 2021;27:19–28. doi:10.1016/j.euros.2021.02.008
   PubMedGoogle Scholar
• Mazzola R, Francolini G, Triggiani L, et al. Metastasis-directed Therapy (SBRT) Guided by PET-CT 18F-CHOLINE Versus PET-CT 68Ga-PSMA in Castration-sensitive Oligorecurrent Prostate Cancer: a Comparative Analysis of Effectiveness. Clin Genitourin Cancer. 2021;19:230–236. doi:10.1016/j.clgc.2020.08.002
   PubMed Web of Science ®Google Scholar
• Albisinni S, Tafuri A, Pirozzi M, et al. A systematic review of imaging-guided metastasis-directed therapy for oligorecurrent prostate cancer: revolution or devolution? Minerva Urol Nefrol;2020. 72. doi:10.23736/S0393-2249.19.03586-0
   PubMed Web of Science ®Google Scholar
• Sritharan K, Rieu R, Tree A. A narrative review of oligometastatic prostate cancer—an evolving paradigm. Ann Palliat Med. 2021;10:5969–5987. doi:10.21037/apm-20-1215
   PubMed Web of Science ®Google Scholar
• De Bleser E, Jereczek-Fossa BA, Pasquier D, et al. Metastasis-directed therapy in treating nodal oligorecurrent prostate cancer: a multi-institutional analysis comparing the outcome and toxicity of stereotactic body radiotherapy and elective nodal radiotherapy. Eur Urol. 2019;76:732–739. doi:10.1016/j.eururo.2019.07.009
   PubMed Web of Science ®Google Scholar
• Ost P, Reynders D, Decaestecker K, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol. 2018;36:446–453. doi:10.1200/JCO.2017.75.4853
   PubMed Web of Science ®Google Scholar
• Deek MP, Phillips RM, Tran PT. Local Therapies in Oligometastatic and Oligoprogressive Prostate Cancer. Semin Radiat Oncol. 2021;31:242–249. doi:10.1016/j.semradonc.2021.03.007
   PubMed Web of Science ®Google Scholar
• Perez-Lopez R, Tunariu N, Padhani AR, et al. Imaging diagnosis and follow-up of advanced prostate cancer: clinical perspectives and state of the art. Radiology. 2019;292:273–286. doi:10.1148/radiol.2019181931
   PubMed Web of Science ®Google Scholar
• Rao A, Vapiwala N, Schaeffer EM, Ryan CJ. Oligometastatic prostate cancer: a shrinking subset or an opportunity for cure? Am Soc Clin Oncol Educ Book. 2019;309–320. doi:10.1200/EDBK_239041
   PubMedGoogle Scholar
• Hövels AM, Heesakkers RAM, Adang EM, et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol. 2008;63:387–395. doi:10.1016/j.crad.2007.05.022
   PubMed Web of Science ®Google Scholar
• Shen G, Deng H, Hu S, Jia Z. Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis. Skeletal Radiol. 2014;43:1503–1513. doi:10.1007/s00256-014-1903-9
   PubMed Web of Science ®Google Scholar
• Farolfi A, Koschel S, Murphy DG, Fanti S. PET imaging in urology: a rapidly growing successful collaboration. Curr Opin Urol. 2020;Publish Ahead of Print. doi:10.1097/MOU.0000000000000800
   Web of Science ®Google Scholar
• Lecouvet FE, Oprea-Lager DE, Liu Y, et al. Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group. Lancet Oncol. 2018;19:e534–e545. doi:10.1016/S1470-2045(18)30571-0
   PubMed Web of Science ®Google Scholar
• Farolfi A, Hadaschik B, Hamdy FC, et al. Positron emission tomography and whole-body magnetic resonance imaging for metastasis-directed therapy in hormone-sensitive oligometastatic prostate cancer after primary radical treatment: a systematic review. Eur Urol Oncol. 2021:S2588931121000377. doi:10.1016/j.euo.2021.02.003
   Web of Science ®Google Scholar
• Gillessen S, Attard G, Beer TM, et al. Management of Patients with Advanced Prostate Cancer: the Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. 2018;73:178–211. doi:10.1016/j.eururo.2017.06.002
   PubMed Web of Science ®Google Scholar
• FDA approves new diagnostic imaging agent FLUCICLOVINE F-18 to detect recurrent prostate cancer « New Drug Approvals. Available from: https://newdrugapprovals.org/2016/05/28/fda-approves-new-diagnostic-imaging-agent-fluciclovine-f-18-to-detect-recurrent-prostate-cancer/. Accessed December 10, 2021.
   Google Scholar
• Axumin® (fluciclovine F 18) injection | terms & Conditions. Available from: https://www.axumin.com/sites/default/files/2018-03/Axumin_PI_08_2016_Clean. Accessed December 10, 2021.
   Google Scholar
• Kim EH, Siegel BA, Teoh EJ, Andriole GL. Prostate cancer recurrence in patients with negative or equivocal conventional imaging: a role for 18F-fluciclovine-PET/CT in delineating sites of recurrence and identifying patients with oligometastatic disease. Urol Oncol Semin Orig Investig. 2021;39:365.e9–365.e16.
   Web of Science ®Google Scholar
• Andriole GL, Kostakoglu L, Chau A, et al. The Impact of Positron Emission Tomography with 18F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: results from the LOCATE Trial. J Urol. 2019;201:322–331. doi:10.1016/j.juro.2018.08.050
   PubMed Web of Science ®Google Scholar
• Woo S, Suh CH, Kim SY, Cho JY, Kim SH. The diagnostic performance of MRI for detection of lymph node metastasis in bladder and prostate cancer: an updated systematic review and diagnostic meta-analysis. Am J Roentgenol. 2018;210:W95–W109. doi:10.2214/AJR.17.18481
   PubMed Web of Science ®Google Scholar
• Padhani AR, Lecouvet FE, Tunariu N, et al. METastasis reporting and data system for prostate cancer: practical guidelines for acquisition, interpretation, and reporting of whole-body magnetic resonance imaging-based evaluations of multiorgan involvement in advanced prostate cancer. Eur Urol. 2017;71:81–92. doi:10.1016/j.eururo.2016.05.033
   PubMed Web of Science ®Google Scholar
• Sweeney CJ, Chen Y-H, Carducci M, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015;373:737–746. doi:10.1056/NEJMoa1503747
   PubMed Web of Science ®Google Scholar
• Gravis G, Fizazi K, Joly F, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, Phase 3 trial. Lancet Oncol. 2013;14:149–158. doi:10.1016/S1470-2045(12)70560-0
   PubMed Web of Science ®Google Scholar
• Kyriakopoulos CE, Chen Y-H, Carducci MA, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED Trial. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36:1080–1087. doi:10.1200/JCO.2017.75.3657
   PubMed Web of Science ®Google Scholar
• Barata PC, Sartor AO. Metastatic castration‐sensitive prostate cancer: abiraterone, docetaxel, or …. Cancer. 2019;125:1777–1788. doi:10.1002/cncr.32039
   PubMed Web of Science ®Google Scholar
• Sweeney CJ, Martin AJ, Stockler MR, et al. Overall survival of men with metachronous metastatic hormone-sensitive prostate cancer treated with enzalutamide and androgen deprivation therapy. Eur Urol. 2021;80:275–279. doi:10.1016/j.eururo.2021.05.016
   PubMed Web of Science ®Google Scholar
• Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381:121–131. doi:10.1056/NEJMoa1903835
   PubMed Web of Science ®Google Scholar
• Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. ARCHES: a randomized, phase iii study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2019;37:2974–2986. doi:10.1200/JCO.19.00799
   PubMed Web of Science ®Google Scholar
• Armstrong AJ, Shore ND, Szmulewitz RZ, et al. Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses. J Urol. 2021;205:1361–1371. doi:10.1097/JU.0000000000001568
   PubMed Web of Science ®Google Scholar
• Sathianathen NJ, Koschel S, Thangasamy IA, et al. Indirect comparisons of efficacy between combination approaches in metastatic hormone-sensitive prostate cancer: a systematic review and network meta-analysis. Eur Urol. 2020;77:365–372. doi:10.1016/j.eururo.2019.09.004
   PubMed Web of Science ®Google Scholar
• Madan RA, Gulley JL. Finding an immunologic beachhead in the prostate cancer microenvironment. J Natl Cancer Inst. 2019;111:219–220. doi:10.1093/jnci/djy145
   PubMedGoogle Scholar
• Zhao SG, Lehrer J, Chang SL, et al. The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target. J Natl Cancer Inst. 2019;111:301–310. doi:10.1093/jnci/djy141
   PubMedGoogle Scholar
• Patel D, McKay R, Parsons JK. Immunotherapy for Localized Prostate Cancer: the Next Frontier? Urol Clin North Am. 2020;47:443–456. doi:10.1016/j.ucl.2020.07.008
   PubMed Web of Science ®Google Scholar
• Hasan H, Deek MP, Phillips R, et al. A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS). BMC Cancer. 2020;20(492). doi:10.1186/s12885-020-07000-2
   PubMed Web of Science ®Google Scholar
• Privé BM, Peters SMB, Muselaers CHJ, et al. Lutetium-177-PSMA-617 in Low-volume hormone-sensitive metastatic prostate cancer: a Prospective Pilot Study. Clin Cancer Res Off J Am Assoc Cancer Res. 2021;27:3595–3601. doi:10.1158/1078-0432.CCR-20-4298
   PubMed Web of Science ®Google Scholar
• Privé BM, Janssen MJR, van Oort IM, et al. Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial. Trials. 2021;22(768). doi:10.1186/s13063-021-05733-4
   PubMed Web of Science ®Google Scholar
• Kucharczyk MJ, Gravis G, Niazi T. The biology of oligometastatic prostate cancer: a different beast than polymetastatic prostate cancer. Eur Urol Focus. 2019;5:117–118. doi:10.1016/j.euf.2018.11.011
   PubMedGoogle Scholar
• Lussier YA, Xing HR, Salama JK, et al. MicroRNA expression characterizes oligometastasis(es). PLoS One. 2011;6(e28650):e28650. doi:10.1371/journal.pone.0028650
   PubMed Web of Science ®Google Scholar
• Lussier YA, Khodarev NN, Regan K, et al. Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs. PLoS One. 2012;7(e50141):e50141. doi:10.1371/journal.pone.0050141
   PubMed Web of Science ®Google Scholar
• Joice GA, Rowe SP, Pienta KJ, Gorin MA. Oligometastatic prostate cancer: shaping the definition with molecular imaging and an improved understanding of tumor biology. Curr Opin Urol. 2017;27:533–541. doi:10.1097/MOU.0000000000000449
   PubMed Web of Science ®Google Scholar
• Dhondt B, De Bleser E, Claeys T, et al. Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer: not ready for prime time. World J Urol. 2019;37:2557–2564. doi:10.1007/s00345-018-2609-8
   PubMed Web of Science ®Google Scholar
• Zhang W, Wu Y, Zhang Z, et al. Controlling Nutritional Status score: a new prognostic indicator for patients with oligometastatic prostate cancer. Curr Probl Cancer. 2019;43:461–470. doi:10.1016/j.currproblcancer.2019.02.001
   PubMed Web of Science ®Google Scholar
• Sonpavde G. The biology of prostate cancer metastases: does oligo differ from polymetastatic? Curr Opin Urol. 2017;27:542–546. doi:10.1097/MOU.0000000000000434
   PubMed Web of Science ®Google Scholar
• Li Y, Tang Z-Y, Ye S-L, et al. Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97. World J Gastroenterol. 2001;7:630–636. doi:10.3748/wjg.v7.i5.630
   PubMed Web of Science ®Google Scholar
• Uppal A, Wightman SC, Mallon S, et al. 14q32-encoded microRNAs mediate an oligometastatic phenotype. Oncotarget. 2015;6:3540–3552. doi:10.18632/oncotarget.2920
   PubMed Web of Science ®Google Scholar
• Reyes DK, Pienta KJ. The biology and treatment of oligometastatic cancer. Oncotarget. 2015;6:8491–8524. doi:10.18632/oncotarget.3455
   PubMedGoogle Scholar
• Arancio W, Belmonte B, Castiglia M, Di Napoli A, Tripodo C. Tissue Versus Liquid Biopsy: opposite or Complementary? In: Russo A, Giordano A, Rolfo C editors. Liquid Biopsy in Cancer Patients: The Hand Lens for Tumor Evolution. Springer International Publishing; 2017:41–49. doi:10.1007/978-3-319-55661-1_4
   Google Scholar
• Ghosh RK, Pandey T, Dey P. Liquid biopsy: a new avenue in pathology. Cytopathol off J Br Soc Clin Cytol. 2019;30:138–143. doi:10.1111/cyt.12661
   PubMed Web of Science ®Google Scholar
• Stelcer E, Konkol M, Głȩboka A, Suchorska WM. Liquid Biopsy in Oligometastatic Prostate Cancer-A Biologist’s Point of View. Front Oncol. 2019;9(775). doi:10.3389/fonc.2019.00775
   PubMed Web of Science ®Google Scholar
• Wang J, Ni J, Beretov J, et al. Exosomal microRNAs as liquid biopsy biomarkers in prostate cancer. Crit Rev Oncol Hematol. 2020;145(102860):102860. doi:10.1016/j.critrevonc.2019.102860
   PubMed Web of Science ®Google Scholar
• Hegemann M, Stenzl A, Bedke J, et al. Liquid biopsy: ready to guide therapy in advanced prostate cancer? BJU Int. 2016;118:855–863. doi:10.1111/bju.13586
   PubMed Web of Science ®Google Scholar
• Gkountela S, Castro-Giner F, Szczerba BM, et al. Circulating Tumor Cell Clustering Shapes DNA Methylation to Enable Metastasis Seeding. Cell. 2019;176:98–112.e14. doi:10.1016/j.cell.2018.11.046
   PubMed Web of Science ®Google Scholar
• Faugeroux V, Lefebvre C, Pailler E, et al. An Accessible and Unique Insight into Metastasis Mutational Content Through Whole-exome Sequencing of Circulating Tumor Cells in Metastatic Prostate Cancer. Eur Urol Oncol. 2020;3:498–508. doi:10.1016/j.euo.2018.12.005
   PubMed Web of Science ®Google Scholar
• Mandel PC, Huland H, Tiebel A, et al. Enumeration and Changes in Circulating Tumor Cells and Their Prognostic Value in Patients Undergoing Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer-Translational Research Results from the Prospective ProMPT trial. Eur Urol Focus. 2021;7:55–62. doi:10.1016/j.euf.2019.05.008
   PubMedGoogle Scholar
• Barriere G, Fici P, Gallerani G, et al. Circulating tumor cells and epithelial, mesenchymal and stemness markers: characterization of cell subpopulations. Ann Transl Med. 2014;2:109. doi:10.3978/j.issn.2305-5839.2014.10.04
   PubMedGoogle Scholar
• Magbanua MJM, Solanki TI, Ordonez AD, Hsiao F, Park JW. Enumeration of Circulating Tumor Cells and Disseminated Tumor Cells in Blood and Bone Marrow by Immunomagnetic Enrichment and Flow Cytometry (IE/FC). Methods Mol Biol Clifton NJ. 1634;203–210:2017.
   Google Scholar
• Togo S, Katagiri N, Namba Y, et al. Sensitive detection of viable circulating tumor cells using a novel conditionally telomerase-selective replicating adenovirus in non-small cell lung cancer patients. Oncotarget. 2017;8(21):34884–34895. doi:10.18632/oncotarget.16818
   PubMedGoogle Scholar
• Mansilla C, Soria E, Ramírez N. The identification and isolation of CTCs: a biological Rubik’s cube. Crit Rev Oncol Hematol. 2018;126:129–134. doi:10.1016/j.critrevonc.2018.03.027
   PubMed Web of Science ®Google Scholar
• Lowes LE, Bratman S, Dittamore R, et al. Circulating Tumor Cells (CTC) and Cell-Free DNA (cfDNA) Workshop 2016: scientific Opportunities and Logistics for Cancer Clinical Trial Incorporation. Int J Mol Sci. 2016;17:E1505. doi:10.3390/ijms17091505
   PubMed Web of Science ®Google Scholar
• Elshimali YI, Khaddour H, Sarkissyan M, Wu Y, Vadgama JV. The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients. Int J Mol Sci. 2013;14:18925–18958. doi:10.3390/ijms140918925
   PubMed Web of Science ®Google Scholar
• Salvi S, Gurioli G, De Giorgi U, et al. Cell-free DNA as a diagnostic marker for cancer: current insights. OncoTargets Ther. 2016;9:6549–6559. doi:10.2147/OTT.S100901
   PubMed Web of Science ®Google Scholar
• Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259–269. doi:10.1038/nrc1840
   PubMed Web of Science ®Google Scholar
• Zabolotneva AA, Zhavoronkov A, Garazha AV, Roumiantsev SA, Buzdin AA. Characteristic patterns of microRNA expression in human bladder cancer. Front Genet. 2012;3(310):2521.
   Google Scholar
• Hessvik NP, Sandvig K, Llorente A. Exosomal miRNAs as Biomarkers for Prostate Cancer. Front Genet. 2013;4(36). doi:10.3389/fgene.2013.00036
   PubMedGoogle Scholar
• Mulrane L, McGee SF, Gallagher WM, O’Connor D. miRNA dysregulation in breast cancer. Cancer Res. 2013;73:6554–6562. doi:10.1158/0008-5472.CAN-13-1841
   PubMed Web of Science ®Google Scholar
• Cheng HH, Plets M, Li H, et al. Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. The Prostate. 2018;78(2):121–127. doi:10.1002/pros.23452
   PubMed Web of Science ®Google Scholar
• Dhondt B, Rousseau Q, De Wever O, Hendrix A. Function of extracellular vesicle-associated miRNAs in metastasis. Cell Tissue Res. 2016;365:621–641. doi:10.1007/s00441-016-2430-x
   PubMed Web of Science ®Google Scholar
• Al-Kafaji G, Said HM, Alam MA, Al Naieb ZT. Blood-based microRNAs as diagnostic biomarkers to discriminate localized prostate cancer from benign prostatic hyperplasia and allow cancer-risk stratification. Oncol Lett. 2018;16:1357–1365. doi:10.3892/ol.2018.8778
   PubMed Web of Science ®Google Scholar
• Bhagirath D, Yang TL, Bucay N, et al. microRNA-1246 Is an Exosomal Biomarker for Aggressive Prostate Cancer. Cancer Res. 2018;78(7):1833–1844. doi:10.1158/0008-5472.CAN-17-2069
   PubMed Web of Science ®Google Scholar
• Paziewska A, Mikula M, Dabrowska M, et al. Candidate diagnostic miRNAs that can detect cancer in prostate biopsy. Prostate. 2018;78(3):178–185. doi:10.1002/pros.23427
   PubMed Web of Science ®Google Scholar
• Tu J, Peng Q, Shen Y, et al. Identification of biomarker microRNA-mRNA regulatory pairs for predicting the docetaxel resistance in prostate cancer. J Cancer. 2019;10:5469–5482. doi:10.7150/jca.29032
   PubMed Web of Science ®Google Scholar
• Cochetti G, Vermandois JA, Maulà V, et al. Role of miRNAs in prostate cancer: do we really know everything? Urol Oncol Semin Orig Investig. 2020;38:623–635.
   PubMed Web of Science ®Google Scholar